Compass shows safety in first psilocybin trial for PTSD, but efficacy data still to come

Readers with a keen interest in the decades-long development of psychedelic-assisted therapy could be forgiven for thinking Christmas has come early. Less than a week after the first-ever request for approval of an MDMA treatment landed on the FDA’s desk, Compass Pathways has reported phase 2 safety data from the first clinical trial of psilocybin in post-traumatic stress disorder (PTSD).